Roche draws emerging markets battle lines with launch of cut-price Herceptin and MabThera in India
This article was originally published in Scrip
Executive Summary
Roche has launched cut-price brands for Herceptin (trastuzumab) and MabThera (rituximab) locally in India but underscored the role of governments in sustaining healthcare plans in their countries.